As of 6 Nov 2026, Lyka Labs is loss-making on a trailing 12-month basis, with a net loss of ₹8.90 Cr, so it has no P/E ratio. The share price is ₹78.62, 18% below its 52-week high. Sales grew 12% a year over 3 years. Debt is 0.54× equity. It is a small-cap company with a market cap of ₹284 Cr, ranked 14th of 20 Biotechnology companies by market cap; the shares fell 19% over the past year.
- ₹78.62
- ₹78.62
- ₹77.50
- ₹77.08
- 7.6K
Health check
- ReturnsBehind
−18.6% over a year, better than 1 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- GrowthUnder pressure
Sales +12.1% a year over 3 years, but loss-making now.
- ProfitabilityNegative
ROCE -7.9% vs peer median 16.7%.
- Balance sheetStretched
Debt 0.54× equity, operating profit doesn’t cover interest, Piotroski 2 of 9.
- Red flags3 to check
Loss-making over the last twelve months.
Small cap
Moves with the market
Key metrics
- Market cap
- ₹284 Cr
- Small cap
- P/E
- n/a
- Industry 49.1
- Price to book
- 3.04
- Peers 4.68
- Dividend yield
- 0.00%
- ROE
- −10.2%
- Peers 14.3%
- ROCE
- −7.9%
- Peers 16.7%
- Debt to equity
- 0.54
- Debt ₹49 Cr
- EPS (TTM)
- −₹2.50
- Face value ₹10
- OPM (TTM)
- −2.0%
- Net margin −6.6%
- Sales growth
- +28.1%
- Latest quarter vs a year ago
- Profit growth
- +121.7%
- Latest quarter vs a year ago
- Price to sales
- 2.12
- EV/EBITDA −72.3
Strengths and risks
Strengths
- Quarterly profit up 121.7% on a year ago.
- Quarterly sales up 28.1% on a year ago.
- Positive operating cash flow in each of the last 4 years.
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at −10.2%.
- Interest coverage of only −1.8×.
About Lyka Labs
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations for human and animal healthcare in India and internationally. It offers injectable critical care solutions, anti-infectives, antifungals, anti-ulcer therapies, oncology support, cardiovascular therapies, and women's healthcare solutions such as gonadotropins, hormonal therapies, and haematinic formulations. The company also develops pharmaceutical…
- Headquarters
- Mumbai
- Employees
- 648
- Sector
- Healthcare
- ISIN
- INE933A01014
- Website
- lykalabs.com
Price range
- Avg volume (3M)
- 18.8K
- 1-year return
- minus 18.6%
- From 52-week high
- minus 17.6%
Peers · Biotechnology
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BIOCONBiocon | 365.10 | plus 0.86% | 59,794 | 122.5 | 1.73 | 2.8% | 1.0% | 20.5% | 15.3% | −5.9% | 0.14% | minus 4.9% |
| ANTHEMAnthem Biosciences | 915.55 | plus 0.22% | 51,594 | 84.6 | 15.74 | 26.8% | 20.4% | 41.4% | 26.2% | 15.4% | 0.22% | plus 30.1% |
| ONESOURCEOnesource Specialty Pharma | 1,599.80 | plus 1.13% | 18,346 | – | 3.10 | 0.3% | 0.0% | 23.5% | 232.3% | – | 0.00% | minus 13.7% |
| CONCORDBIOConcord Biotech | 632.60 | minus 5.96% | 13,236 | 47.4 | 6.48 | 16.7% | 14.3% | 34.5% | 8.0% | 2.8% | 0.56% | minus 7.5% |
| BLUEJETBlue Jet Healthcare | 553.80 | minus 3.91% | 9,607 | 34.5 | 4.52 | 24.0% | 19.9% | 31.4% | 9.4% | 15.7% | 0.21% | minus 5.0% |
| SUPRIYASupriya Lifescience | 695.80 | minus 19.99% | 5,600 | 28.2 | 4.68 | 22.3% | 19.1% | 21.4% | 21.2% | 32.5% | 0.11% | plus 9.2% |
| ZOTAZota Health Care | 1,231.10 | plus 1.01% | 4,264 | – | 6.82 | −7.3% | −24.1% | 0.1% | 56.7% | – | 0.08% | minus 21.9% |
| LYKALABSLyka Labs | 78.62 | plus 2.00% | 284 | – | 3.04 | −7.9% | −10.2% | 6.0% | 12.1% | – | 0.00% | minus 18.6% |
| Median of 7 peers | – | 0.22% | 13,236 | 47.4 | 4.68 | 16.7% | 14.3% | 23.5% | 21.2% | 15.4% | 0.14% | −5.0% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 33 | 36.7 | 30.7 | 28 | 42.3 | |
| 29.3 | 39.2 | 29.1 | 34.5 | 37.8 | |
| 3.7 | −2.5 | 1.6 | −6.5 | 4.5 | |
| 11.2% | −6.9% | 5.4% | −23.0% | 10.7% | |
| 0.6 | 1.1 | 1.2 | 0.6 | 0.4 | |
| 0.9 | 0.8 | 0.8 | 0.7 | 1 | |
| 2.1 | 2.1 | 2.2 | 2 | 2 | |
| 1.4 | −4.4 | −0.2 | −8.6 | 1.9 | |
| 26.3% | 26.7% | 5.6% | 6.1% | −5.1% | |
| 0.9 | −3.4 | −0 | −7.6 | 2.1 | |
| 0.25 | -0.94 | – | -2.13 | 0.57 |
Profit & loss
- Sales CAGR 3Y
- +12.1%
- ROE
- −10.2%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 88.3 | 105 | 134 | 124 | |
| – | +19.0% | +27.0% | minus 6.9% | |
| 75.6 | 89.4 | 116 | 128 | |
| 12.7 | 15.8 | 18 | −4.1 | |
| 14.4% | 15.0% | 13.4% | −3.3% | |
| 7.4 | 1.2 | 2 | 3 | |
| 11.7 | 4.7 | 2.1 | 2.2 | |
| 14.1 | 12.8 | 6.8 | 8.5 | |
| −7.4 | −0.4 | 0 | – | |
| −13.2 | −0.9 | 11.1 | −11.8 | |
| 0.1% | −180.6% | 28.7% | 11.4% | |
| −13.2 | −2.5 | 8 | −10 | |
| -4.63 | -0.75 | 2.22 | -2.81 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 30.7 | 33.1 | 35.7 | 35.7 | |
| 14.8 | 35.1 | 69.1 | 56.7 | |
| 73.7 | 57.7 | 38.2 | 48.9 | |
| 32.4 | 31 | 33.3 | 33.3 | |
| 152 | 157 | 176 | 175 | |
| 63.8 | 71.1 | 77.3 | 86.7 | |
| 15.2 | 24.3 | 0.4 | 6.3 | |
| 0 | 0.1 | 0 | – | |
| 14 | 3.4 | 5 | 5.4 | |
| 58.5 | 58 | 93.5 | 76.1 | |
| 152 | 157 | 176 | 175 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 9 | 1.8 | 1.9 | 5.2 | |
| 7.4 | −9.5 | −11.8 | −9.4 | |
| −21.6 | 2 | 5.3 | 4.2 | |
| −5.3 | −5.8 | −4.6 | 0 | |
| −8.2 | −9.2 | −15.7 | −11.1 | |
| 0.8 | −7.5 | −13.8 | −5.9 |
Shareholding pattern
- Promoters58.45%
- Public41.55%
| Quarter | Split | Promoters | Public | Promoter change |
|---|---|---|---|---|
| 30 Sep 2026 | 58.45% | 41.55% | 0.00 | |
| 30 Jun 2026 | 58.45% | 41.55% | plus 0.29 | |
| 31 Mar 2026 | 58.16% | 41.84% | 0.00 | |
| 31 Dec 2025 | 58.16% | 41.84% | 0.00 | |
| 30 Sep 2025 | 58.16% | 41.84% | – |
Major shareholders
Filings & events
News
No recent news coverage found.